Compounding: Groups Tell FDA To Drop “Traditional” and “Non-Traditional” Categories
Executive Summary
Stakeholders say it would create more confusion in the pharmacy and regulatory community; they also spar over whether volume, other criteria should be imposed to distinguish compounding types.
You may also be interested in...
Drug Shortages: FDA Says Market Must Reward Production Quality
FDA officials state in journal article that manufacturers are not incentivized to ensure quality and base competition entirely on price.
FDA Shortage Notification Mandate May Not Extend To Biologics
The agency has the option to issue regulations requiring biologics manufacturers to notify FDA of emerging production problems, but so far it’s only “something that we’re thinking about.”
‘Imminent’ Generic Approvals Expected To Help US FDA Meet On-Time Review Metric Retroactively
ANDA action rate dipped below the 90% mandate in second fiscal quarter, another illustration of the effect the pandemic and other issues have on US FDA’s generic drug assessment system.